Canada · Delayed Price · Currency is CAD MustGrow Biologics Earnings Call Transcripts
Fiscal Year 2026
-
TerraSante sales reached ~CAD 875,000 by Aug. 15, 2026, up 46% vs. 2025, while production constraints continue to limit supply. Bayer’s registration program for TerraMG has reached its first milestone payment, and broader commercialization depends on regulatory approvals and capacity expansion.
-
Q2 2026 saw TerraSante sales rise 46% year-over-year, with strong demand in strawberries and potatoes, but gross margins were pressured by costly air freight. Manufacturing improvements and a shift to ocean freight are expected to restore margins and support positive cash flow in 2027.
-
Q1 2026 saw the first TerraSante sales, improved margins, and a narrowed focus after discontinuing NexusBioAg. Manufacturing issues limited Q1 growth, but demand is strong and management expects a stronger second half, with international expansion and capital raises supporting growth.
Fiscal Year 2025
-
2025 sales fell short due to NexusBioAg underperformance, but TerraSante sales surged 377% year-over-year. Focus is now on expanding TerraSante in the U.S. and globally, with improved margins expected in 2026 and cash flow breakeven targeted for 2027.
-
Q3 2025 saw seasonally low sales and no TerraSate revenue due to inventory shortages, but gross margin improved to 22%. Strong demand for TerraSate and new product launches are expected to drive a robust Q4 and a positive outlook for 2026, with break-even targeted next year.